Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.64 USD | +2.01% | +6.40% | -5.00% |
11/04 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
22/03 | B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.00% | 376M | |
+29.68% | 681B | |
+25.07% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.68% | 235B | |
+4.71% | 199B | |
-12.43% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- HROW Stock
- News Harrow, Inc.
- Harrow Health Rolls out Iopidine 1%, Maxitrol in US; Plans to Launch Moxeza 0.5% Later